Before accepting the apparent efficacy of D@C-LP chemotherapy, it is necessary to confirm the rationale of exposed CLDN4 as a therapeutic target in an orthotopic pancreatic tumor model. This evidence concerns the gene CLDN4 and pancreatic neoplasm.